Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
It's official: dramatic share price jumps in response to clinical data have become more common.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.